Vascular Biology |
From the Department of Biological Sciences (R.C.P., I.H.) and the Department of Developmental Biology and Anatomy (C.V.P.), School of Medicine, University of South Carolina, Columbia.
Correspondence to Rekha C. Patel, Department of Biological Sciences, University of South Carolina, 700 Sumter St, Columbia, SC 29208. E-mail patelr{at}sc.edu
Objective The proliferation of vascular smooth muscle cells (VSMCs) in blood vessels after endothelial injury contributes to the onset of atherosclerosis. Heparin is a potent antiproliferative agent for VSMCs in vivo and in vitro. Although heparin has shown promise in suppressing VSMC proliferation after invasive procedures in laboratory animals, the mechanism of its antiproliferative actions is largely unknown. Here, we present evidence for the first time that the antiproliferative action of heparin is in part mediated by its ability to activate double-stranded RNA-activated protein kinase (PKR), an interferon-induced protein kinase.
Methods and Results We have analyzed the VSMC proliferation by cell-cycle analysis and correlated it to the kinase activity of PKR in the presence of heparin. Heparin treatment of VSMCs results in activation of PKR by direct binding and results in a block in G1- to S-phase transition. PKR-null cells are largely insensitive to the antiproliferative actions of heparin, and inhibition of PKR in VSMCs results in a partial abrogation of the antiproliferative effects of heparin.
Conclusions These results invoke the involvement of novel PKR-dependent regulatory pathways in mediating the antiproliferative actions of heparin.
Key Words: vascular smooth muscle cell proliferation heparin RNA-activated protein kinase cell cycle interferon
This article has been cited by other articles:
![]() |
M. Mittelstadt, A. Frump, T. Khuu, V. Fowlkes, I. Handy, C. V. Patel, and R. C. Patel Interaction of human tRNA-dihydrouridine synthase-2 with interferon-induced protein kinase PKR Nucleic Acids Res., February 11, 2008; 36(3): 998 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xu, G. Rao, R. M. Quiros, A. W. Kim, H.-Q. Miao, G. J. Brunn, J. L. Platt, P. Gattuso, and R. A. Prinz In Vivo and in Vitro Degradation of Heparan Sulfate (HS) Proteoglycans by HPR1 in Pancreatic Adenocarcinomas: LOSS OF CELL SURFACE HS SUPPRESSES FIBROBLAST GROWTH FACTOR 2-MEDIATED CELL SIGNALING AND PROLIFERATION J. Biol. Chem., January 26, 2007; 282(4): 2363 - 2373. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yu, D. A. Quinn, H. G. Garg, and C. A. Hales Cyclin-Dependent Kinase Inhibitor p27Kip1, But Not p21WAF1/Cip1, Is Required for Inhibition of Hypoxia-Induced Pulmonary Hypertension and Remodeling by Heparin in Mice Circ. Res., October 28, 2005; 97(9): 937 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wessely Interference by interferons: Janus faces in vascular proliferative diseases Cardiovasc Res, June 1, 2005; 66(3): 433 - 443. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fasciano, R. C. Patel, I. Handy, and C. V. Patel Regulation of Vascular Smooth Muscle Proliferation by Heparin: INHIBITION OF CYCLIN-DEPENDENT KINASE 2 ACTIVITY BY p27kip1 J. Biol. Chem., April 22, 2005; 280(16): 15682 - 15689. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |